The reduction of the inflammatory biomarker IL-6 following inhaled IFN-α2b therapy not only supported a clinically relevant impact of this approach, but also hinted at likely functional connections between viral infection and host end organ damage. This evidence concerns the gene IL6 and viral infectious disease.